Iovance Biotherapeutics (FRA:2LB) Inventories, Work In Process: €0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2LB Iovance Biotherapeutics Inc FRA:2LB
34 GF Score
Price €5.54
GF Value €15.86
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Iovance Biotherapeutics Inventories, Work In Process?

Iovance Biotherapeutics FRA:2LB +1.84% 34 Inventories, Work In Process is €0.0 Mil as of Jun. 2026. GuruFocus rates FRA:2LB with a GF Score™ of 34/100 and a GF Value™ of €15.86 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Iovance Biotherapeutics's work in process for the quarter that ended in Jun. 2026 was €0.0 Mil.

Iovance Biotherapeutics Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Iovance Biotherapeutics's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iovance Biotherapeutics Inventories, Work In Process Chart

Iovance Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 5.27 8.37 0.00

Iovance Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2LB
34GF Score
Iovance Biotherapeutics Inc FRA:2LB
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Iovance Biotherapeutics Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €0.0 Mil mean?
Iovance Biotherapeutics (FRA:2LB) has a Inventories, Work In Process of €0.0 Mil as of Jun. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Iovance Biotherapeutics and its competitors.
Is Iovance Biotherapeutics' Inventories, Work In Process too high?
Iovance Biotherapeutics' current Inventories, Work In Process is €0.0 Mil. Overall, Iovance Biotherapeutics has a GF Score™ of 34/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Inventories, Work In Process compare to SLS and NUVB?
Iovance Biotherapeutics' Inventories, Work In Process of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Iovance Biotherapeutics and its competitors. Iovance Biotherapeutics's current Inventories, Work In Process is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (FRA:2LB) is currently considered Significantly Undervalued. The stock's GF Value™ is €15.86, compared to a current price of €5.54 — trading 65.1% below its estimated fair value. The current Inventories, Work In Process is €0.0 Mil. Iovance Biotherapeutics' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Iovance Biotherapeutics (FRA:2LB), the current Inventories, Work In Process is €0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Iovance Biotherapeutics (FRA:2LB) Overvalued in 2026?

Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued. The current stock price of €5.54 is trading 65.1% below its estimated GF Value™ of €15.86. GuruFocus considers Iovance Biotherapeutics to be Significantly Undervalued.

Key valuation signals for FRA:2LB:

  • Inventories, Work In Process: €0.0 Mil
  • GF Value™: €15.86 vs. price of €5.54 (65.1% below fair value)
  • GF Score™: 34/100 with 3 warning signs

No single metric tells the full story. See the FRA:2LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Iovance Biotherapeutics Business Description

Address 825 Industrial Road, Suite 100, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
34GF Score

Get the complete analysis for FRA:2LB

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.54
Price
€15.86
GF Value